CN113166239A - 抗il-17a抗体及其应用 - Google Patents
抗il-17a抗体及其应用 Download PDFInfo
- Publication number
- CN113166239A CN113166239A CN201980082789.0A CN201980082789A CN113166239A CN 113166239 A CN113166239 A CN 113166239A CN 201980082789 A CN201980082789 A CN 201980082789A CN 113166239 A CN113166239 A CN 113166239A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
一种以高亲和力与IL‑17A特异性结合的抗体或其功能性片段。一种编码上述抗体或其功能性片段的核酸分子,用于表达抗体或其功能性片段的表达载体和宿主细胞,以及抗体或其功能性片段的生产方法。一种包含抗体或其功能性片段的药物组合物,以及使用抗体或其功能性片段治疗免疫功能失调性疾病的方法。
Description
PCT国内申请,说明书已公开。
Claims (18)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811515045.7A CN111303283A (zh) | 2018-12-12 | 2018-12-12 | 抗il-17a抗体及其应用 |
CN2018115150457 | 2018-12-12 | ||
PCT/CN2019/124486 WO2020119707A1 (zh) | 2018-12-12 | 2019-12-11 | 抗il-17a抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113166239A true CN113166239A (zh) | 2021-07-23 |
CN113166239B CN113166239B (zh) | 2022-11-04 |
Family
ID=71075299
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811515045.7A Pending CN111303283A (zh) | 2018-12-12 | 2018-12-12 | 抗il-17a抗体及其应用 |
CN201980082789.0A Active CN113166239B (zh) | 2018-12-12 | 2019-12-11 | 抗il-17a抗体及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811515045.7A Pending CN111303283A (zh) | 2018-12-12 | 2018-12-12 | 抗il-17a抗体及其应用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230159632A1 (zh) |
EP (1) | EP3896086A4 (zh) |
JP (1) | JP2022513224A (zh) |
KR (1) | KR20210102946A (zh) |
CN (2) | CN111303283A (zh) |
AU (1) | AU2019397309A1 (zh) |
BR (1) | BR112021011257A2 (zh) |
CA (1) | CA3123124A1 (zh) |
IL (1) | IL283881A (zh) |
MX (1) | MX2021007028A (zh) |
SG (1) | SG11202106128TA (zh) |
WO (1) | WO2020119707A1 (zh) |
ZA (1) | ZA202104048B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113769082A (zh) * | 2020-06-10 | 2021-12-10 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体药物组合物及其用途 |
CN115746132B (zh) * | 2021-09-03 | 2023-09-08 | 三优生物医药(上海)有限公司 | 抗il-17a抗体及其用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103936854A (zh) * | 2014-04-30 | 2014-07-23 | 北京精益泰翔技术发展有限公司 | 抗il-17a单克隆抗体及其制备与应用 |
CN104250302A (zh) * | 2013-06-26 | 2014-12-31 | 上海君实生物医药科技有限公司 | 抗pd-1抗体及其应用 |
WO2015137843A1 (ru) * | 2014-03-14 | 2015-09-17 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
CN105073775A (zh) * | 2013-02-08 | 2015-11-18 | 诺华股份有限公司 | 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途 |
US20170291939A1 (en) * | 2014-06-25 | 2017-10-12 | Novartis Ag | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK2578685T3 (da) | 2005-08-23 | 2019-06-03 | Univ Pennsylvania | Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf |
WO2013090186A1 (en) | 2011-12-14 | 2013-06-20 | modeRNA Therapeutics | Modified nucleic acids, and acute care uses thereof |
AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
CN106474470B (zh) * | 2015-08-28 | 2020-05-22 | 江苏恒瑞医药股份有限公司 | 一种抗il-17a抗体的组合物 |
CA3036913C (en) * | 2016-09-14 | 2023-05-16 | Beijing Hanmi Pharm. Co., Ltd. | Antibody specifically binding to il-17a and functional fragment thereof |
CN107522783B (zh) * | 2017-09-30 | 2020-07-07 | 华博生物医药技术(上海)有限公司 | 一种抗白介素17a的抗体、其制备方法和应用 |
-
2018
- 2018-12-12 CN CN201811515045.7A patent/CN111303283A/zh active Pending
-
2019
- 2019-12-11 CN CN201980082789.0A patent/CN113166239B/zh active Active
- 2019-12-11 CA CA3123124A patent/CA3123124A1/en active Pending
- 2019-12-11 SG SG11202106128TA patent/SG11202106128TA/en unknown
- 2019-12-11 US US17/413,152 patent/US20230159632A1/en active Pending
- 2019-12-11 JP JP2021534214A patent/JP2022513224A/ja active Pending
- 2019-12-11 MX MX2021007028A patent/MX2021007028A/es unknown
- 2019-12-11 BR BR112021011257-0A patent/BR112021011257A2/pt unknown
- 2019-12-11 KR KR1020217021674A patent/KR20210102946A/ko unknown
- 2019-12-11 AU AU2019397309A patent/AU2019397309A1/en active Pending
- 2019-12-11 EP EP19897274.7A patent/EP3896086A4/en active Pending
- 2019-12-11 WO PCT/CN2019/124486 patent/WO2020119707A1/zh unknown
-
2021
- 2021-06-10 IL IL283881A patent/IL283881A/en unknown
- 2021-06-11 ZA ZA2021/04048A patent/ZA202104048B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105073775A (zh) * | 2013-02-08 | 2015-11-18 | 诺华股份有限公司 | 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途 |
CN104250302A (zh) * | 2013-06-26 | 2014-12-31 | 上海君实生物医药科技有限公司 | 抗pd-1抗体及其应用 |
WO2015137843A1 (ru) * | 2014-03-14 | 2015-09-17 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
CN103936854A (zh) * | 2014-04-30 | 2014-07-23 | 北京精益泰翔技术发展有限公司 | 抗il-17a单克隆抗体及其制备与应用 |
US20170291939A1 (en) * | 2014-06-25 | 2017-10-12 | Novartis Ag | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
Also Published As
Publication number | Publication date |
---|---|
EP3896086A4 (en) | 2022-09-07 |
US20230159632A1 (en) | 2023-05-25 |
CA3123124A1 (en) | 2020-06-18 |
ZA202104048B (en) | 2023-12-20 |
CN111303283A (zh) | 2020-06-19 |
WO2020119707A1 (zh) | 2020-06-18 |
IL283881A (en) | 2021-07-29 |
KR20210102946A (ko) | 2021-08-20 |
CN113166239B (zh) | 2022-11-04 |
BR112021011257A2 (pt) | 2021-08-31 |
SG11202106128TA (en) | 2021-07-29 |
AU2019397309A1 (en) | 2021-07-29 |
JP2022513224A (ja) | 2022-02-07 |
MX2021007028A (es) | 2021-09-10 |
EP3896086A1 (en) | 2021-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1163271B1 (en) | Recombinant il-18 antibodies and their use | |
US10738112B2 (en) | Anti-human interleukin-17A monoclonal antibody | |
US9809647B2 (en) | Neutralizing anti-CCL20 antibodies | |
JP5255453B2 (ja) | Par−2に結合する抗体 | |
KR20060123148A (ko) | Il-18 결합 단백질 | |
CA3101670C (en) | Anti-il-23p19 antibody and use thereof | |
KR20100014568A (ko) | 가공된 항-il-23r 항체 | |
US20050070692A1 (en) | Anti-interleukin-1 beta analogs | |
CN113166239B (zh) | 抗il-17a抗体及其应用 | |
CN114437212B (zh) | 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用 | |
CN117337302A (zh) | 用抗il23特异性抗体治疗对tnf疗法响应不足的银屑病关节炎患者的方法 | |
EP2240517B1 (en) | Fdf03 antibodies and uses thereof | |
KR20230156764A (ko) | 항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법 | |
RU2816204C2 (ru) | Антитело против il-17a и его применение | |
CN112513078B (zh) | 抗il-17a抗体及其用途 | |
WO2023116759A1 (zh) | 抗bcma抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40057229 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |